Developed by Eli Lilly as a triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, retatrutide achieved a mean body weight reduction of -24.2% at its highest dose over 48 weeks surpassing both semaglutide and tirzepatide in their respective pivotal trials
Concomitant diseases of patients in this trial included, but were not limited to, heart failure (12%), history of ischemic stroke (8%) and history of a MI (36%)
What the research actually says This section matters more than any other in this guide
Frequent consumption of diet soda is unlikely to reduce the medicines effectiveness but may impact overall dietary balance if it replaces healthier drink choices
White House launches digital health initiative backed by leading tech firms. July 30, 2025
Semaglutide has emerged as a groundbreaking treatment for obesity, rapidly gaining attention for its impressive weight loss results